FDA approves Gilead’s Vemlidy sNDA for paediatric HBV patients

Vemlidy is now indicated for treating HBV infection in children aged six years and above weighing a minimum of 25kg with compensated liver disease. Credit: Drew Gilliam on Unsplash.